Page 8 - Dror Bashan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results

Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHa afonTel avivDror bashanChiesi farmaceuticiContactchuck padalaBen zviMyrld holidaShmuel muliProtalix biotherapeutics incCompany linkEuropean commissionUniversity of iowa stead family children hospitalDrug administrationCompensation committeeAudit committee

CHMP recommends first pegylated enzyme for Fabry disease

A PEGylated enzyme replacement therapy for Fabry disease has received a positive opinion from the EMA's human medicines committee.

Dror bashanGiacomo chiesiProtalix biotherapeuticsEuropean medicines agencyEuropean commissionCommittee for medicinal products human useMedicinal productsHuman useChief executive officerChiesi global rare diseases

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease

/PRNewswire/ Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected.

United statesUnited kingdomHa afonDror bashanAdam daleyChiesi farmaceuticiGiacomo chiesiChuck padalaProtalix biotherapeutics incB corpEuropean commissionDrug administrationExchange commissionPfizer incBerry company public relationsChiesi group

Protalix BioTherapeutics Issues 2023 Letter to Stockholders

/PRNewswire/ Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and.

United statesHa afonDror bashanChiesi farmaceuticiChuck padalaProtalix biotherapeutics incDrug administrationPrnewswire protalix biotherapeutics incExchange commissionPfizer incEuropean unionEuropean medicines agencyChief executive officerProtalix shareholdersMarketing authorization applicationBiologics license application

Four Israeli cos expect FDA approvals in 2023

Treatments for blood cancer and rare diseases are the target markets, but investors are well aware of the challenges that await after approval is received.

Israel generalHa afonTel avivAbigail jenkinsDror bashanAlpha galactosidaseGenzyme sanofiOfer gonenPhilip serlinAmicus therapeuticsYork stock exchangeDrug administrationClal biotechnology industriesNew york stock exchangeTel aviv stock exchangeTeva pharmaceutical industries